论文部分内容阅读
目的分析黄体酮阴道缓释凝胶在体外受精-胚胎移植(IVF-ET)黄体支持中的有效性和安全性。方法选择2015年1~12月于我中心接受长方案IVF-ET助孕患者992例,按照不同的黄体支持方案进行分组:黄体酮60 mg肌内注射组(A组)56例,黄体酮40 mg肌内注射组(B组)740例,黄体酮阴道缓释凝胶外用组(C组)196例。比较三组患者的妊娠率、种植率、多胎率、流产率和异位妊娠率及药物不良反应发生率。结果三组的妊娠率、种植率、多胎率、流产率、异位妊娠率比较,差异无统计学意义(P>0.05),但是C组妊娠率、多胎率、种植率有增高趋势,流产率有降低趋势。C组的药物总不良反应发生率明显低于A、B两组,差异有统计学意义(P<0.01)。结论黄体酮阴道缓释凝胶是有效、安全的IVF-ET黄体支持方法之一。
Objective To analyze the efficacy and safety of progesterone-releasing vaginal sustained-release gel in corpus luteum support of in vitro fertilization-embryo transfer (IVF-ET). Methods A total of 992 pregnant women with long-term IVF-ET were enrolled in our center from January to December 2015. The patients were divided into different groups according to the luteal supportive regimen: progesterone 60 mg intramuscular injection group (group A) 56 cases, progesterone 40 mg intramuscular injection group (group B) 740 cases, progesterone vaginal sustained release gel external use group (group C) 196 cases. The pregnancy rate, implantation rate, multiple birth rate, miscarriage rate, ectopic pregnancy rate and incidence of adverse drug reactions in the three groups were compared. Results There was no significant difference in pregnancy rate, implantation rate, multiple birth rate, abortion rate and ectopic pregnancy rate among the three groups (P> 0.05). However, pregnancy rate, multiple birth rate and implantation rate in group C tended to increase. Abortion rate There is a downward trend. The incidence of adverse drug reactions in group C was significantly lower than that in group A and B (P <0.01). Conclusions Progesterone vaginal sustained release gel is one of the effective and safe IVF-ET luteal support methods.